Genomate Health is thrilled to announce its participation in the 2024 Annual Meeting of the American Society of Clinical Oncology (#ASCO24), where we will present not one but two pioneering research abstracts. Our team, represented by Istvan Petak, MD, PhD, Barbara Vodicska, PhD, Anna Dirner, and Robert Doczi, PhD, is honored to contribute to the ongoing advancement of precision oncology.

ASCO is the leading global oncology conference, bringing together experts and innovators who are shaping the future of cancer treatment. At this prestigious event, Genomate Health will showcase its cutting-edge research in digital drug-assignment and predictive AI-driven oncology solutions, further solidifying our mission to enhance patient outcomes through precision medicine.

Algorithmic Precision in Immune Checkpoint Therapy Response Prediction for Lung Cancer

Authors: Barbara Vodicska , Eniko Kispeter , Csenge Somodi , Robert Doczi , Dora Lakatos , Dora Tihanyi , Anna Dirner , Reka Szalkai-Denes , Matyas Vidermann , Marton Bolyacz , Akos Takacs , Maria Kocsis-Steinbach , Anna Varjassy , Maud Kamal , Christophe Le Tourneau , Istvan Petak

Our first abstract, Algorithmic precision in immune checkpoint therapy response prediction for lung cancer: Evaluating the Digital Drug Assignment model's clinical performance, highlights the clinical performance of our AI-driven Digital Drug Assignment (DDA, commercially known as Genomate) model. This research, led by Barbara Vodicska, PhD, and a distinguished team of scientists, evaluates how algorithmic precision can improve immune checkpoint therapy response predictions in lung cancer patients. By leveraging advanced AI methodologies, our model aims to enhance treatment selection, ultimately increasing therapeutic success rates and minimizing ineffective interventions. Read the full abstract.

Real-World Performance of the Digital Drug-Assignment System for Precision Oncology in Lung Cancer

Authors: Anna Dirner , Robert Doczi , Dora Kormos , Dora Lakatos , Marton Bolyacz , Dora Tihanyi , Akos Takacs , Akos Boldizsar , Maria Kocsis-Steinbach , Barbara Vodicska , Reka Szalkai-Denes , Edit Varkondi , Julia Deri , Dora Mathiasz , Istvan T. Valyi-Nagy , Richard Schwab , Maud Kamal , Christophe Le Tourneau , Laszlo Urban , Istvan Petak

The second abstract, Real-world performance of the digital drug-assignment system for precision oncology in lung cancer, spearheaded by Anna Dirner and Robert Doczi, PhD, delves into the effectiveness of our precision oncology system in clinical settings. This study evaluates the real-world application of our DDA system in lung cancer treatment, providing critical insights into its impact on patient outcomes and clinical workflows. The findings reinforce the value of AI-powered precision oncology in making personalized treatment more accessible and efficient. Read the full abstract.

Genomate Health is proud to stand at the forefront of oncology innovation, and our participation at ASCO 2024 underscores our commitment to revolutionizing cancer treatment through computational intelligence-driven precision medicine. We look forward to engaging with fellow researchers, clinicians, and industry leaders to discuss the future of personalized oncology care.

Stay tuned for more insights from ASCO 2024 as we continue to push the boundaries of what’s possible in cancer treatment.

‍